There’s a Promising New HIV Vaccine in Trials

A recent European Pharmaceutical Review article discussed a novel HIV vaccine that has shown promise in its first human Phase I trial. The vaccine is in development to become a primer that activates B cells through germline-targeting. The hope is that these specialized blood proteins could adhere to the HIV surface proteins that allow the virus to enter human cells, and disable them.